Literature DB >> 2424755

Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.

M Grabe, A Forsgren, T Björk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2424755     DOI： 10.1007/bf02013991

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Short antibiotic courses in transurethral prostatic resection.

Authors:  M Grabe
Journal:  Scand J Urol Nephrol Suppl       Date:  1984

2.  Bacteriuria in patients undergoing prostatectomy.

Authors:  M Williams; D J Hole
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

3.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

4.  Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.

Authors:  A Forsgren
Journal:  Scand J Infect Dis       Date:  1985

5.  Ciprofloxacin distribution in prostatic tissue and fluid following oral administration.

Authors:  J B Boerema; A Dalhoff; F M Debruyne
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544
  5 in total
  12 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble.

Authors:  Deepak K Pruthi; Michael A Liss
Journal:  Nat Rev Urol       Date:  2017-05-23       Impact factor: 14.432

3.  A new method for assaying antimicrobials in the prostate.

Authors:  A C Philpott; E D Crawford; G J Miller
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 4.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

5.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

Review 6.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery.

Authors:  M Grabe; A Forsgren; T Björk; S Hellsten
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 8.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Use of quinolones in treatment of prostatitis and lower urinary tract infections.

Authors:  V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.

Authors:  A Forsgren; S F Schlossman; T F Tedder
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.